Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel
Orangutan undergoes chemotherapy
Image: J Pat Carter/AP
First for orangutan cancer treatment

An eight-year-old orangutan has undergone chemotherapy treatment at Miami Zoo Jungle Island, Florida.

The orangutan, named Peanut, has aggressive non-Hodgkin lymphoma (cancer of the blood). She was diagnosed following examinations for an intestinal obstruction and is the first documented orangutan to undergo chemotherapy.

Peanut has been undergoing chemotherapy since August. Three other orangutans, all in their 30s and 40s, have been known to undergo cancer treatment in the past, though they received either radiation therapy or operations to remove their tumours.

Orangutans share about 96 percent of a human's genetics, so her treatment is close to what a human would receive for the same type of cancer, however, she is given slightly reduced doses. Unless her body can't handle it, Peanut will receive six three-hour doses, each 21 days apart. Her doses are one or two hours less than given to humans.

I've never had the same combination of fear and enthusiasm in one patient before
Unlike humans, Peanut has been sedated for the treatments, though vomited after her first therapy. It is not known whether this was caused by the treatment or the anaesthesia - which is known to cause nausea in animals.

One of the doctors treating Peanut, Joseph Rosenblatt, said: "I've never had the same combination of fear and enthusiasm in one patient before. We don't know what to expect and yet we're intensely curious and potentially hopeful that we can help the animal."

Dr Rosenblatt has never worked with an animal larger than a mouse, but he adds: "When the animal looks at you in the eye, it's both sympathetic as well as a look that radiates intelligence."

Image: J Pat Carter/AP
Peanut is able to use sign language and uses an iPad to communicate with her trainers. The team say she is very welcoming - offering her doctor a twig in return for a water bottle. With age on her side, it is thought that Peanut stands a good chance of being cured following her therapy, or at least experiencing remission.

The team say they are keeping a positive attitude around her, though she is highly intelligent and she understands something is different with her. Her trainers believe she would not comprehend what cancer or illness is.

Peanut's trainer, Linda Jacobs, said Peanut is fatigued but hasn't lost much of her reddish-orange hair.

"I have been with her since she was born, so I am really sensitive to her needs and her moods," she said. "She still has that twinkle in her eye, and God willing, she will be a cancer survivor."

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.